Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -1066.69% is 512% below its 5-year average of -174.21%, near the low end of its 5-year range (-1066.69%–-25.42%).
239.55% below its 12-month average of -314.14%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -255.12%.
RETURN ON ASSETS (ROA)
-1066.69%
RETURN ON ASSETS (ROA) AVG TTM
-314.14%
RETURN ON ASSETS (ROA) AVG 3Y
-238.72%
RETURN ON ASSETS (ROA) AVG 5Y
-174.21%
RETURN ON ASSETS (ROA) AVG 10Y
-314.04%
RETURN ON ASSETS (ROA) AVG 15Y
-215.72%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-239.55%
CURRENT VS 3Y AVG
-346.83%
CURRENT VS 5Y AVG
-512.32%
CURRENT VS 10Y AVG
-239.66%
CURRENT VS 15Y AVG
-394.47%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-3208.59%
vs the sector median at left
GlucoTrack, Inc.
Market Cap
$897911.00
Return on Assets (ROA)
-1066.69%
TTM Avg
-314.14%
3Y Avg
-238.72%
5Y Avg
-174.21%
Market Cap
$858810.00
Return on Assets (ROA)
-17.34%
TTM Avg
-18.34%
3Y Avg
-35.92%
5Y Avg
-162.42%
Market Cap
$857758.00
Return on Assets (ROA)
-65.16%
TTM Avg
-80.06%
3Y Avg
-104.26%
5Y Avg
-73.53%
Market Cap
$849293.00
Return on Assets (ROA)
-63.04%
TTM Avg
-106.06%
3Y Avg
-121.33%
5Y Avg
-96.21%
Market Cap
$845829.00
Return on Assets (ROA)
-160.53%
TTM Avg
-148.83%
3Y Avg
-175.96%
5Y Avg
-127.43%
Market Cap
$812262.00
Return on Assets (ROA)
N/A
TTM Avg
7.00%
3Y Avg
-3.42%
5Y Avg
-4.05%
Market Cap
$832147.00
Return on Assets (ROA)
N/A
TTM Avg
-16.55%
3Y Avg
-16.64%
5Y Avg
-15.27%
Market Cap
$1.03M
Return on Assets (ROA)
-81.60%
TTM Avg
-1375.39%
3Y Avg
-681.84%
5Y Avg
-547.21%
Market Cap
$1.06M
Return on Assets (ROA)
-44.32%
TTM Avg
-57.72%
3Y Avg
-286.30%
5Y Avg
-215.47%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GlucoTrack, Inc. (GCTK) | $897911.00 | -1066.69% | -314.14% | -238.72% | -174.21% |
| Sunshine Biopharma, Inc. (SBFM)vs › | $858810.00 | -17.34% | -18.34% | -35.92% | -162.42% |
| Bone Biologics Corporation (BBLG)vs › | $857758.00 | -65.16% | -80.06% | -104.26% | -73.53% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $849293.00 | -63.04% | -106.06% | -121.33% | -96.21% |
| Decoy Therapeutics Inc. (DCOY)vs › | $845829.00 | -160.53% | -148.83% | -175.96% | -127.43% |
| Ridgetech, Inc. (RDGT)vs › | $812262.00 | N/A | 7.00% | -3.42% | -4.05% |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $832147.00 | N/A | -16.55% | -16.64% | -15.27% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | -81.60% | -1375.39% | -681.84% | -547.21% |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | -44.32% | -57.72% | -286.30% | -215.47% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | -8.84% | -4.56% | 8.88% | 8.88% |
ROA
-1066.7%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -247.36% |
| 2024-12-31 | -380.93% |
| 2023-12-31 | -144.69% |
| 2022-12-31 | -181.91% |
| 2021-12-31 | -64.92% |
| 2020-12-31 | -25.42% |
| 2019-12-31 | -320.80% |
| 2018-12-31 | -975.81% |
| 2017-12-31 | -618.89% |
| 2016-12-31 | -219.82% |
| 2015-12-31 | -273.94% |
| 2014-12-31 | 46.95% |
| 2013-12-31 | -355.45% |
| 2012-12-31 | -340.34% |
| 2011-12-31 | -108.33% |
| 2010-12-31 | 0.00% |
| 2009-12-31 | 0.00% |
